市場調查報告書
商品編碼
1069309
醫療用薄膜:全球市場的展望(2021年~2028年)Medical Membranes - Global Market Outlook (2021 - 2028) |
全球醫療用薄膜的市場規模,從2021年的28億1,000萬美元,預計到2028年達到52億美元,在預測期間內預計以9.2%的年複合成長率成長。
本報告提供全球醫療用薄膜市場相關調查分析,市場趨勢分析,各市場區隔、各地區的市場資訊,企業簡介等資訊。
According to Stratistics MRC, the Global Medical Membranes Market is accounted for $2.81 billion in 2021 and is expected to reach $5.20 billion by 2028 growing at a CAGR of 9.2% during the forecast period. Medical membranes are created synthetically for use in separation process across laboratories or healthcare industry. The membrane technology is of major importance in medical applications, in particular in a number of lifesaving treatment methods. Its major-medical applications include artificial organs; drug delivery; tissue regeneration; and diagnostic devices, such as medical device coatings and bio-separations. The membrane is used to cover some of the improved applications of membrane technologies, such as concentration, separation, and purification, as a separation technique. Medical membranes have high precision for separation and assist in the processing of products of high purity.
Market Dynamics:
Driver:
Rising demand in emerging economies
Emerging markets such as China, India, Brazil, and other developing countries present significant opportunities for players involved in pharmaceutical production and in the dialysis treatment sector. The rising need for ultra-pure water for pharmaceutical manufacturing and hemodialysis is driving the demand for medical membranes in emerging regions. Contract manufacturing for medical products is also on the rise in countries such as India and China. The demand for dialysis products and services in these countries is increasing due to rising incidence of ESRD. The demand is also supported by growth in aging population, rising incidence of diabetes, hypertension, and increasing awareness about kidney disorders.
Restraint:
Lifespan of membranes
The medical membranes used in various procedures are prone to fouling, after which, they do not have the same operational excellence. The lifespan of a particular type of membrane used in a separation process for medical application is constrained and, therefore, needs replacement after a certain period of time. During the treatment of pharmaceutical water or during any filtration/purification process, some unwanted components such as sulfate, iron, manganese, calcium, and other ions form precipitate on the membrane surface. For example, if the RO feed contains a high concentration of material, it may foul the membrane and reduce the life expectancy of the membrane. It is a challenge for the market players to produce membranes that last longer or does not foul easily.
Opportunity:
Growing demand for artificial organs
The incidents of organ failures are on the rise with changing lifestyle. This is leading to high demand for organ transplant. The number of patient demanding organ transplant is continuously increasing compared to the number of donors donating organs. The US, Japan, Germany, Brazil, and Italy are the major countries with high demand for renal replacement therapy. The demand and supply gap of organ transplant is increasing rapidly. Thus, with the growing supply-demand gap, the trend of organ transplant is diminishing slowly and is substituted by artificial organ replacement. The yearly growth rate for dialysis patients is more than 7-8%. This growth fuels the demand for medical membranes. The demand for these artificial organs is also driving the medical membranes market.
Threat:
Long in-process validation process
Despite the high demand for medical products and devices, manufacturers are facing several regulatory barriers due to multi-layered regulations set by the FDA. In the US, for the approval of any new medical product, manufacturers are required to submit performance data to the FDA. The medical membranes, though made of medical grade polymers, have to undergo in-process validation for certification. This process takes 3-6 months. After the membrane or membrane component has been validated and certified, the device that uses the membrane also needs to be certified. In this process, the device is compared with a legally marketed device for the same use and the same technological characteristics. Thus, these lengthy validation and certification process delays the commercialization of medical membranes and medical products thereby posing a major threat for the market.
The nanofiltration segment is expected to be the largest during the forecast period
The nanofiltration segment is estimated to have a lucrative growth owing to the fact that with increase in flow rates, nanofiltration is achieved at reduced operating pressures. Nanofiltration membrane only rejects multivalent ions with no selectivity towards monovalent ions, whereas RO rejects all the solutes including monovalent ions. This property enables nanofiltration membranes to operate at greatly reduced operating pressures with greatly increased flow rates as compared to RO. Thus, the use of nanofiltration process technology is gaining momentum. Also, research & development in solvent-stable membranes has allowed the application of nanofiltration membranes to extend into new areas such as pharmaceuticals and fine chemicals.
The polysulfone (PSU) & polyether sulfone (PESU) segment is expected to have the highest CAGR during the forecast period
The polysulfone (PSU) & polyether sulfone (PESU) segment is anticipated to witness the fastest CAGR growth during the forecast period. These materials are widely used and promising material in medical applications and waste-treatment membranes as it provides excellent mechanical and thermal properties. The high demand for PSU & PESU is due to the excellent properties offered by these materials and its increasing demand in pharmaceutical filtration and hemodialysis application. PESU is an inherently hydrophilic membrane that provides fast filtration and superior flow rate and is used for aqueous solutions to remove fine particles, bacteria, and fungi.
Region with highest share:
Europe is projected to hold the largest market share during the forecast period. Europe is a significant contributor to the global demand for medical membrane. Its growth is fuelled by the growing end-stage renal disease (ESRD) patient pool, increasing availability of better diagnosis facilities, and high incidence and prevalence of chronic diseases such as diabetes and hypertension. Europe, a leader in pharmaceutical manufacturing and dialyzer demand. Diabetes and hypertension covered around 60% of the total end stage renal disease cases in Europe.
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR over the forecast period. Significant growth of the market in countries such as India and China is expected to boost the market in Asia Pacific during the forecast period. Rising prevalence of diabetes, growing demographics, and expanding medical care industry are expected to drive the medical membrane market in these countries. Health care costs are increasing at a rate twice the country's economic growth rate. In China, where most people in the country are insured, health care spending is rising at a rate of 16% per year. Leading companies are also present in Asia Pacific, and others are eager to expand their business in the region to take advantage of the region's high demand. The robust healthcare sector in emerging markets such as India and China presents enormous opportunities. Other areas, such as Australia and Indonesia, have seen an increase in demand, opening up new opportunities for manufacturers.
Key players in the market
Some of the key players profiled in the Medical Membranes Market include Asahi Kasei, Atlas Copco, Danaher Corporation, GE Healthcare, Hangzhou Cobetter Filtration Equipment, Koch Membrane Systems, Mann+Hummel, Merck Group, Microdyn-Nadir GmbH, Pall Corporation, Precision Medical, Sartorius AG, and W. L. Gore & Associates.
Key Developments:
In July 2021, Asahi Kasei MedicalOpen new window has decided to expand production capacity of hydrophilic PVDF (polyvinylidene fluoride) hollow-fiber membranes for Planova™ BioEX filters at its spinning plant in Oita, Japan. The global COVID-19 pandemic has increased the urgent demand for Planova™ filters, which are indispensable to develop and mass-produce anti-coronavirus agents. Asahi Kasei Medical will double spinning production capacity at this site by utilizing its state-of-the-art technology.
In March 2020, Danaher Corporation has agreed to divest assets to settle Federal Trade Commission charges that its proposed $21.4 billion acquisition of General Electric's biopharmaceutical business, GE Biopharma, would violate federal antitrust law. The FTC alleges that the proposed acquisition would substantially lessen competition in the United States (and potentially the rest of the world) in highly concentrated product markets for ten products that companies use to manufacture biopharmaceutical drugs.
Technologies Covered:
Materials Covered:
Distribution Channels Covered:
Applications Covered:
End Users Covered:
Regions Covered:
What our report offers:
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.